Cannabis & Alternatives — Federal rescheduling catalyzes pharma interest, MSO consolidation, and a fraught DEA registration process for cannabis operators

Cannabis & Alternatives · 2026-05-01

TODAY'S SIGNAL — The cannabis industry is entering a decisive post-rescheduling implementation phase that is simultaneously opening doors and creating legal minefields. Pharmaceutical firms are circling the sector with fresh capital interest now that Schedule III status reduces stigma for institutional investors—a dynamic that is emboldening MSOs like Vireo Growth, TerrAscend, and Verano to make…